ArticleMaterials today. Bio2026
A multifunctional mitochondria-targeted nanoparticle for the effective treatment of dry eye disease via reactive oxygen species scavenging.
Article in Materials today. Bio, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Nanoscale biointerfaces in inter-organelle communication: membrane contact sites, organelle trafficking, and cell fate control.Frontiers in cell and developmental biology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Dry eye disease is a prevalent ocular surface disorder primarily driven by oxidative stress and inflammation, remains a therapeutic challenge due to the limitations of current treatments. In this study, we developed a multifunctional nanoparticle system, using a layer-by-layer self-assembly strategy to enhance the delivery and efficacy of a natural antioxidant, proanthocyanidin (PC). The nanocomplex consists of a caseinate-proanthocyanidin core, further modified with chitosan-triphenylphosphonium (CS-TPP) for mitochondrial targeting and coated with hyaluronic acid (HA) to prolong ocular surface retention. In vitro and in vivo studies demonstrated that PC-Casein/CS-TPP/HA (CCH@PC) effectively scavenges reactive oxygen species with an elimination efficiency of up to 70 %, protects mitochondrial function, and significantly extends corneal residence time compared to conventional eye drops. Moreover, in a murine model of dry eye, CCH@PC markedly alleviated clinical symptoms, effectively promotes the tear secretion of the dry eye model mice, increasing from 2.20 mm to 5.06 mm, suppressed inflammatory responses, and promoted corneal epithelial repair. These findings highlight the potential of CCH@PC as a targeted, sustained, and multifunctional nanotherapeutic platform for treating dry eye disease and other oxidative stress-related ocular pathologies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.